Truist Cuts Hims & Hers Health, Inc. (HIMS) Price Target, Cites Mixed Revenue Outlook

Hims & Hers Health, Inc. (NYSE:HIMS) is one of the best Russell 2000 stocks to buy now. On August 18, Truist Securities lowered its price target on Hims & Hers from $48 to $37, while maintaining a Hold rating. Despite an 8% dip over the past week, the stock remains up 195% year-over-year, trading at $46.02.

Truist Cuts Hims & Hers Health, Inc. (HIMS) Price Target, Cites Mixed Revenue Outlook

Source: Unsplash

Truist expects modest GLP-1 revenue growth in Q3 and Q4, aided by deferred revenue and the Zava acquisition, which may help meet the lower end of guidance. However, the firm flagged concerns about 2026 growth, emphasizing its revenue mix analysis over app downloads or MAU metrics.

Hims & Hers Health, Inc. (NYSE:HIMS) is a consumer-focused telehealth company. It provides personalized healthcare and wellness services through a digital platform that connects patients with licensed medical professionals. The company offers treatments across various categories, including sexual health, mental health, dermatology, and primary care.

While we acknowledge the potential of Hims & Hers Health, Inc. (NYSE:HIMS) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than HIMS and that has 100x upside potential, check out our report about the cheapest AI stock.

READ NEXT: 10 Best Energy Stocks to Buy For the Long Term and Top 10 Industrial Stocks to Buy Amid Easing Tariff Uncertainties.

Disclosure: None. This article is originally published at Insider Monkey.